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ORIGINAL ARTICLE
Sevoflurane attenuates systemic inflammation compared
with propofol, but does not modulate neuro-inflammation
A laboratory rat study
Beatrice Beck-SchimmerM, Lukas BaumannM, Tanja Restin, Philipp Eugster, Melanie Hasler,
Christa Booy and Martin Schla¨pfer
BACKGROUND Septic encephalopathy is believed to be a
result of neuro-inflammation possibly triggered by endotox-
ins, such as lipopolysaccharides (LPS). Modulation of the
immune system is a property of volatile anaesthetics.
OBJECTIVE We aimed to investigate the systemic and
cerebral inflammatory response in a LPS-induced sepsis
model in rats. We compared two different sedation strate-
gies, intravenous propofol and the volatile anaesthetic sevo-
flurane, with the hypothesis that the latter may attenuate
neuro-inflammatory processes.
DESIGN Laboratory rat study.
SETTING Basic research laboratories at the University Hos-
pital Zurich and University Zurich Irchel between August
2014 and June 2016.
PATIENTS A total of 32 adult male Wistar rats.
INTERVENTIONS After tracheotomy and mechanical venti-
lation, the anaesthetised rats were monitored before sepsis
was induced by using intravenous LPS or phosphate-buff-
ered saline as control. Rats were sedated with propofol
(10 mg kg1 h1)orsevoflurane (2vol%)continuously for12 h.
MAIN OUTCOME MEASURES Systemic inflammatory mar-
kers such as cytokine-induced neutrophil chemo-attractant
protein 1, monocyte chemo-tactic protein-1 and IL-6 were
determined. The same cytokines were measured in brain
tissue. Cellular response in the brain was assessed by
defining neutrophil accumulation with myeloperoxidase
and also activation of microglia with ionised calcium-binding
adaptor molecule-1 and astrocytes with glial fibrillary acidic
protein. Finally, brain injury was determined.
RESULTS Animals were haemodynamically stable in both
sedation groups treated with LPS. Blood cytokine peak
values were lower in the sevoflurane-LPS compared with
propofol-LPS animals. In brain tissue of LPS animals, chemo-
attractant protein-1 was the only significantly increased
cytokine (P¼0.003), however with no significance between
propofol and sevoflurane. After LPS challenge, cerebral
accumulation of neutrophils was observed. Microglia acti-
vation was pronounced in the hippocampus of animals
treated with LPS (P¼0.006). LPS induced prominent astro-
gliosis (P<0.001). There was no significant difference in
microglia or astrocyte activation or apoptosis in the brain
between sevoflurane and propofol.
CONCLUSION We have shown that systemic attenuation of
inflammation by the volatile anaesthetic sevoflurane did not
translate into attenuated neuro-inflammation in this LPS-
induced inflammation model.
TRIAL REGISTRATION Animal approval No. 134/2014,
Veterina¨ramt Zu¨rich.
Published online 28 July 2017
Introduction
Sepsis is an overwhelming systemic inflammatory re-
sponse to an infection and carries a high mortality and
morbidity.1,2 Its prevalence is about 1 per 1000 people in
industrialised countries3 and it accounts for 10 to 50% of
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deaths in ICUs.4,5 Septic encephalopathy is one of the
most common complications of sepsis and often precedes
multi-organ failure.6,7 It probably results from neuro-
inflammation, altered cerebral perfusion and imbalance
of neurotransmitters.8 It may present as any kind of
neurological dysfunction and even lead to coma.9 Abnor-
mal electroencephalography patterns have been reported
in more than 80% of septic patients.10 It has been shown
that septic encephalopathy is associated with poorer
outcome in sepsis independent of other organ dysfunc-
tion.11 Recent data indicate that long-term neurological
impairment is common even after recovery from sepsis.12
The importance of cerebral dysfunction in sepsis is
underlined by the quick sepsis-related organ failure
assessment score that aims to identify those suffering
from an infection, who are prone to poor outcome,
including cerebral dysfunction.13
The pathophysiology behind septic encephalopathy is
unclear, and there is no targeted treatment, but it has
been shown that both ischaemic and neuro-inflammatory
processes trigger the development of septic encephalop-
athy during sepsis.14 In-vivo models demonstrate that
septic encephalopathy is accompanied by a disrupted
blood–brain barrier15,16 and that [lipopolysaccharides
(LPS)] exposure induces an astroglial and microglial
inflammatory response,17,18 promoting transmigration of
monocytes and neutrophils.19 More importantly, LPS not
only induces an inflammatory response in the brain, but
also impairs cognitive function in rats and mice.20,21
Sevoflurane is a volatile anaesthetic and sedative, which
reduces endothelial inflammatory response after LPS
exposure in vitro and in vivo.22,23 It also improves survival
rate in septic rats and mice.24,25
The aim of this study was to assess neuronal inflamma-
tion in a LPS-induced sepsis model and to investigate
any immuno-modulation of the inflammatory process by
sevoflurane sedation. We chose to do this by first deter-
mining the release of pro-inflammatory cerebral cyto-
kines such as chemoattractant protein-1 (CINC-1),
monocyte chemotactic protein (MCP) and IL-6 and also
the anti-inflammatory transforming growth factor beta 1
(TGFb1) in LPS-treated animals. We intended to assess
their functional effect, namely recruitment of neutro-
phils as effector cells.Microglial (macrophage) activation
was assessed by measuring ionised calcium-binding
adaptor molecule-1 (Iba-1). To assess whether and
how astroglial inflammatory response, defined as reactive
astrogliosis, in rat brain tissue develops, we measured
astrocytic activation through glial fibrillary acidic protein
(GFAP). Finally, cerebral apoptosis was evaluated.
Based on previous observations in non-neuronal tissue,
we hypothesised that sevoflurane, compared with pro-
pofol, might have an attenuating effect on the accumu-
lation of neutrophils as well as activation of microglia
and astrocytes.
Material and methods
Ethics
The animal experiments were approved by the
Animal Use and Care Committee of the Kanton Zurich
(Veterina¨ramt des Kantons Zu¨rich, Zollstrasse 20, 8090
Zurich, Switzerland, approval No. 134/2014, 1 July 2014).
The trial was registered and given Animal approval
No. 134/2014 by the Veterina¨ramt Zu¨rich.
The animal experiments took place between 18 August
2014 and 12 November 2014. Molecular analyses
followed between December 2014 and June 2016.
Animals
All experiments were carried out on adult male Wistar
rats (Charles River, Sulzfeld, Germany) weighing
329 21 g (corresponding to 9 to11 weeks). Animals were
allowed to adapt for 1 week prior to the experiments.
They were housed in standard rat cages with a 12/12 h
light/dark cycle and free access to food and water.
Animal model and anaesthesia
Despite its limitations, endotoxaemia is accepted as an
in-vivo sepsis model. It allows good control of the degree
of systemic inflammation without evoking animal death.
To avoid any sepsis-induced vascular effects such as
ischaemia, we chose a more haemodynamically stable
model giving priority to the inflammatory component.
An overview of the experimental procedure is given in
Fig. 1a. On the day of the experiment, blocks of two
animals were randomly assigned to four intervention
groups, with eight animals in each group:
(1) propofol-LPS: endotoxaemia induced by LPS, seda-
tion for 12 h with propofol
(2) sevoflurane-LPS: endotoxaemia induced by LPS,
sedation for 12 h with sevoflurane
(3) propofol-PBS: sham procedure with PBS, sedation for
12 h with propofol
(4) sevoflurane-PBS: sham procedure with PBS, sedation
for 12 h with sevoflurane
Anaesthesia was induced with an intra-peritoneal injec-
tion of ketamine, midazolam and fentanyl (100, 3 and
0.015mgkg1, respectively). The common carotid artery
and external jugular vein were cannulated and a trache-
otomy was performed. The lungs were mechanically
ventilated (Servo Ventilator 300; Maquet, Solna,
Sweden). The baseline ventilator settings were: positive
end-expiratory pressure 3 cmH2O; peak inspiratory pres-
sure 14 cmH2O; fraction of inspired oxygen 0.3; respira-
tory rate of 30min1, in line with previous experiments.26
Anaesthesia was maintained by either sevoflurane (2.2%)
or propofol (10mgkg1 h1). The presence of the toe-
pinch reflex was sought, but animals had to be able to
tolerate ventilation without distress. Depth of anaesthe-
sia was tested every 30min and in case of respiratory
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distress, an additional fentanyl bolus of 5mg kg1 was
given. After letting the animals adapt for 10min, baseline
venous and arterial blood samples were drawn for
analyses that included blood gases. The blood samples
taken were replaced in a 1 : 4 ratio with Ringer’s solution
(Ringerfundin; B.Braun, Melsungen, Germany), admin-
istered continuously at 5ml kg1 h1 initially.27 In
response to the blood gas analysis, the respiratory rate
was adjusted for normoventilation (CO2 target range: 35
to 45mmHg).
Endotoxaemia was induced by intravenous LPS
1mgkg1 body weight from Escherichia coli (Sigma-
Aldrich, Buchs, Switzerland), dissolved in 300-ml PBS
(Kantonsapotheke Zurich, Zurich, Switzerland). Sham
animals received PBS only.
Blood gas analyses (Epoc blood gas analyser; Alere,
Waltham, Massachusetts, USA) and venous blood
samplings were repeated every 3 h until the end of the
experiment. Blood samples were placed in heparinised
tubes, centrifuged at 4 8C and 8000 relative centrifugal
force (rcf), and plasma was stored at 80 8C. Animals
were kept at 37 8C throughout the procedure, by using a
heating pad. At the end of the experiment, animals were
sacrificed under deep anaesthesia, and the brain was
removed. The left hemisphere of the brain was sliced
into six sections (Fig. 1b). Half of these were snap-frozen
in liquid nitrogen and stored at 80 8C; the other half
were stored in 4% formaldehyde (Kantonsapotheke
Zurich) for at least 72 h, then formaldehyde was ex-
changed for ethanol (EtOH) 70%, and the sections were
stored at 4 8C until paraffin embedding. The right hemi-
sphere was used for brain water calculation.
Real-time PCR analysis of inflammatory markers in
brain tissue
To isolate total RNA from brain tissue, the RNeasy Mini
Kit (Qiagen, Basel, Switzerland) was used according to
the manufacturer’s protocol. Total RNA amounts and
purity were determined by absorbance at 260 nm and the
absorbance ratio at 260/280 nm by using NanoDrop ND
766 Beck-Schimmer et al.
Fig. 1
Experimental setup
LPS 1mg kg–1 or PBS
(a)
(b)
T0 = 0h
T1 = 3h
T2 = 6h
T3 = 9h
T4 = 12h
Sevoflurane 2.2% or propofol  mg kg–1 h–1
Water
content
1 2 3 4 5 6
Experimental setup with time-line: after a single injection of lipopolysaccharides to induce endotoxaemia or phosphate-buffered saline (sham
animals), male Wistar rats were continuously sedated for 12 h with either propofol (10 mg kg1 h1) or sevoflurane 2.0 vol%. Blood samples were
drawn every 3 h, brain tissue was obtained for histological and biochemical analyses. (a) The left brain hemisphere was cut into six sections and used
for histological and biochemical analyses. The sections used for the individual analyses are described in the corresponding the ‘Material and
methods’ section. Brain water content calculation was performed in the right hemisphere (b).
Eur J Anaesthesiol 2017; 34:764–775
Copyright © European Society of Anaesthesiology. Unauthorized reproduction of this article is prohibited.
1000 (NanoDrop Technologies, Wilmington, Delaware,
USA).
Reverse transcription and real-time quantitative PCR for
CINC-1, MCP-1, IL-6, intercellular adhesion molecule-1
(ICAM-1) and TGFb1 were performed as previously
described.28 Details of forward and reverse primers as
well as the probes used can be found in Table 1.
Protein extraction from neuronal tissue
Frozen sections of the frontal lobe (segment 1, Fig. 1b) of
each specimen were homogenised in lysis buffer (1,4-
dithiothreitol 100mmol l1; protease inhibitor 1 : 500;
phosphatase inhibitor 2þ 3 1 : 100) from Sigma in Hank’s
Balanced Salt Solution (Thermo Fisher Scientific, Rock-
ford, Illinois, USA). Ceramic beads (MagNALyser Green
Beads; Roche Diagnostics, Mannheim, Germany) of a
diameter of 1.4mm were added to the tissue and homo-
genised by using Precellys Tissue Homogeniser (Bertin
Corp., Rockville, Maryland, USA) for 20 s at 5500 rpm.
The lysate was then centrifuged at 4 8C and 300 rcf for
10min and the supernatant collected. Samples were
stored at 20 8C until further analysis was performed.
ELISAs
ELISAs for the inflammatory mediators CINC-1 (R&D
Systems, Abingdon, United Kingdom), MCP-1 (BD Bio-
science, Allschwil, Switzerland) and IL-6 (R&D Sys-
tems) were performed in serum (at 0, 3, 6, 9 and 12 h)
and brain tissue lysate according to the manufacturer’s
protocol. To determine the protein concentration of
brain tissue lysates, a detergent compatible protein assay
(Bio-Rad Laboratories AG, Cressier, Switzerland, Cata-
logue No. 500-0114) was performed as described.
The results from brain tissue lysates were calculated in
pgml1 and were corrected for the amount of protein in
the lysate (divided by the protein content in the solution
in mgml1). The final results are shown as pg cytokine
per mg brain protein.
Formalin fixed, paraffin embedded brain sections
Before embedding in paraffin, the brain tissue was dehy-
drated by using a tissue processor (Microm STP 120;
Thermo, Reinach, CH, Basel, Switzerland) for a total of
17 h with 3 h 70% EtOH, 3 h 80% EtOH, 2 h 90% EtOH,
2 h 96% EtOH, 2 h 100% EtOH, 2 h xylene and 3h
paraffin. In the next morning, the tissue was embedded
by using a paraffin embedding system (Medite TBS 88;
Dietikon, CH, Basel, Switzerland).
Immuno-histochemistry
Paraffin-embedded brain tissue (the ‘Material and meth-
ods’ section, Fig. 1b) was cut into 5-mm thick coronal
sections by using a Zeiss Hyrax M55 microtome (Carl
Zeiss, Jena, Germany). Sections mounted onto Polysine
microscope slides (VWR International, Leuven,
Belgium) were dried on a slide warmer at 37 8C overnight.
To quantify the severity of neuro-inflammation, markers
for neutrophils [myeloperoxidase (MPO), GFAP and
Iba-1] were used. After removing paraffin in 3 5min
Xylene (Sigma), 2 5min in 100% EtOH, 2 5min in
95% EtOH and 1 5min in 75% EtOH, the slides were
washed three times in PBS.
For Iba-1 and MPO, but not for GFAP staining, heat-
induced epitope retrieval in citrate buffer (1.8mmol l1
citric acid, 8.2mmol l1 sodium citrate; both from Sigma)
was undertaken by using a Histos Pro microwave (Mile-
stone SRL, Sorisole, Italy). All sections were blocked
with 5% bovine serum albumin (BSA) solution (KPL,
Gaithersburg, Maryland, USA) in PBS for 1 h at room
temperature (RT). Sections were allowed to incubate
with the primary antibody overnight at 4 8C: Iba-1 goat
anti-rat antibody (Abcam; Catalog No. ab5076; 1 : 500),
MPO rabbit anti-rat antibody (Abcam; Catalog No.
ab9535; 1 : 50) and GFAP rabbit anti-rat (Sigma; Catalog
No. G9269; 1 : 100). After washing in PBS, slides were
incubated with the corresponding secondary antibody
Alexa Fluor 488 donkey anti-goat IgG (Thermo Fisher
Scientific; Catalog No. A-11055; 1 : 500) or Alexa Fluor
568 goat anti-rabbit IgG (Abcam; 1 : 500) and with
40,6-diamidine-20-phenylindole dihydrochloride (DAPI)
1 : 1000 (Roche) for 1 h at RT. All antibodies were diluted
in 0.5% BSA in PBS solution. In a final step, all slides
were mounted with fluorescent mounting medium
(DAKO; Dako North America, Carpinteria, California,
USA) or ProLong Gold anti-fade reagent (Thermo Fisher
Scientific).
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Table 1 Primer sequences and probes used for real-time PCR
Gene Primer sequence
Length of
amplicon
(nt)
CINC-1
Forward 50 CAC ACT CCA ACA GAG CAC CA 30 120
Reverse 50 TGA CAG CGC AGC TCA TTG 30
Probe # 49 50 CAG CCA CC 30
MCP-1
Forward 50 AGC ATC CAC GTG CTG TCT C 30 78
Reverse 50 GAT CAT CTT GCC AGT GAA TGA GT 30
Probe # 62 50 ACC TGC TG 30
IL-6
Forward 50 CCC TTC AGG AAC AGC TAT GAA 30 74
Reverse 50 ACA ACA TCA GTC CCA AGA AGG 30
Probe # 20 50 CTG GCT GG 30
ICAM-1
Forward 50 TTC TGC CAC CAT CAC TGT GT 30 95
Reverse 50 AGC GCA GGA TGA GGT TCT T 30
Probe # 62 50 ACC TGC TG 30
TGFb1
Forward 50 AAG GGC TAC CAT GCC AAC TT 30 92
Reverse 50 TGG TTG TAG AGG GCA AGG AC 30
Probe # 116 50 GAG CCT GG 30
CINC-1, chemoattractant protein-1; ICAM-1; intercellular adhesion molecule-1;
MCP-1, monocyte chemotactic protein-1; TGFb1, transforming growth factor
beta 1.
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Image processing and cell counting
GFAP and Iba-1 sections were evaluated by using a Leica
DM5500 B microscope (Leica Microsystems, Heerbrugg,
Switzerland) and image capture was performed by using a
DFC 360 FX digital camera (Leica Microsystems).
Images of the hippocampal dentate gyrus and retrosple-
nial cortex region (RSC) were taken at random at 20
magnification and then processed by using image analysis
software (ImageJ 1.43; NIH, Bethesda, Maryland, USA).
An identical threshold of the obtained image stacks was
set, images were binarised and positive cells counted with
the ‘analyse particles tool’ in ImageJ (Supplementary
Information 1, http://links.lww.com/EJA/A130). The area
of interest in the dentate gyrus was defined by outlining
the polymorphic cell layer by using the DAPI co-staining.
For each slide, up to four images per examined region
were captured.
To visualise MPO stained brain sections, tile images
with 20 magnification were taken by using an Axio
Scan Z1 Slide Scanner (Carl Zeiss) and automatically
merged by using ZEN 2.0 (Carl Zeiss) software. MPO
immuno-reactive cells in the whole brain section area
were automatically counted by using ImageJ as de-
scribed above. Each identified particle was then manu-
ally verified to be a neutrophil. Then, the number of
MPO positive cells per square millimetre (cellsmm2)
was calculated and divided by the size of the analysed
brain area. All images were post-processed and analysed
in a blinded manner.
Brain water content
The right hemisphere was used for brain water content
calculation. The brain wet weight was determined im-
mediately after removal. The hemispheres were dried for
72 h at 60 8C in the oven and the dry weight was assessed.
Brain water content was calculated as follows: water
[%]¼ 100 (wet weightdry weight)/wet weight.
Determination of apoptotic cells
Neuronal apoptosis was evaluated by using the In Situ
Cell Death Detection Kit (Roche) following manu-
facturers’ instructions. The terminal deoxynucleotidyl
transferase-mediated desoxy-uradyl triphosphate nick
end labelling (TUNEL) reaction labels free 30-OH
termini in an enzymatic reaction and detects double
or single-stranded DNA breaks generated during
apoptosis.
Study endpoints
In summary, the following were measured: mean arterial
pressure, base excess, systemic and brain inflammatory
mediators CINC-1,MCP-1 and IL-6, neutrophils in brain
tissue, activation of microglia lba-1-positive cells, activa-
tion of astrocytes (GFAP expression), brain oedema
formation and the degree of neuronal apoptosis.
Statistical analysis
Data are presented as meanSD. Analyses were per-
formed in GraphPad Prism 6.0 for Mac OS X (GraphPad
Inc, La Jolla, California, USA). Comparisons between
the various groups were assessed by one-way analysis
of variance (ANOVA), when single measurements
were analysed. Repeated measurements were analysed
by two-way ANOVA. Each treatment group was
compared with every other treatment group. To correct
for multiple comparisons, a Tukey post-hoc test
was performed. The significance level was defined as
P less than 0.05.
Results
Vital signs and systemic inflammatory markers
Mean arterial pressure was affected neither by sepsis
nor by the type of sedation (propofol-LPS: 93 13
mmHg, sevoflurane-LPS: 88 6mmHg, propofol-PBS:
105 9mmHg, sevoflurane-PBS: 93 9mmHg, Fig. 2a).
Blood oxygenation (PaO2: propofol-LPS: 153 20
mmHg, sevoflurane-LPS: 156 16mmHg, propofol-
PBS: 160 7mmHg, sevoflurane-PBS: 168 12 mmHg,
all P> 0.8) and ventilation (PaCO2: propofol-LPS:
48 3mmHg, sevoflurane-LPS: 45 4mmHg, propofol-
PBS: 45 3mmHg, sevoflurane-PBS: 41 3mmHg, all
P> 0.5) were similar.
Base excess after 12 h was comparable in both LPS
groups (P¼ 0.77), but lower than in the corresponding
control groups (propofol-PBS: 0.7 2.2mEq l1 vs. pro-
pofol-LPS: 7.3 2.2mEq l1, P< 0.001; sevoflurane-
PBS: 0.2 4.3mEq l1 vs. sevoflurane-LPS: 5.7
2.7mEq l1, P¼ 0.003) (Fig. 2b).
To assess inflammatory markers caused by endotoxae-
mia, plasma levels of CINC-1, MCP-1 and IL-6 were
determined. Concentration of plasma CINC-1 in animals
of both LPS groups peaked at 3 and 12 h. The inflamma-
tory reaction was stronger with propofol than with sevo-
flurane animals (3 h: propofol-LPS vs. sevoflurane-LPS:
532 189 vs. 368 34 ngml1, P¼ 0.004; 12 h: propofol-
LPS vs. sevoflurane-LPS: 401 305 vs. 99 40 ngml1,
P< 0.001, Fig. 2c).
Similarly, a biphasic peak of MCP-1 (3 and 12 h) was
observed in animals treated with LPS with a significant
difference between the two sedative regimens at 12 h
(propofol-LPS vs. sevoflurane-LPS: 5.3 4.2 vs.
2.5 0.5mgml1, P< 0.001, Fig. 2d).
For IL-6 a single peak in LPS animals was found at 6 h.
This was more pronounced in the propofol-LPS than
the sevoflurane-LPS group (32 29 vs. 17 4 ng l1,
P¼ 0.003, Fig. 2e).
mRNA and protein expression of inflammatory markers
in brain tissue in sepsis
mRNA of the inflammatory mediators CINC-1, MCP-1
and IL-6 was upregulated after LPS injection and was
768 Beck-Schimmer et al.
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similar in both sevoflurane-LPS and propofol-LPS groups
(Fig. 3). Only the protein level of CINC-1 was increased
after LPS with no significant difference between the
anaesthetics used (Fig. 4).
Activation of microglia in sepsis
In the dentate gyrus area of the hippocampus, the amount
of Iba-1 positive cells was lower in PBS compared
with LPS animals (propofol-PBS vs. propofol-LPS:
55.1 26.4 vs. 103.7 27.4 cellsmm2, P¼ 0.006; sevo-
flurane-PBS vs. sevoflurane-LPS 55.2 18.8 vs. 123.9
34.2 cellsmm2 P< 0.001). No effect of the type of
sedative was observed in propofol-LPS vs. sevoflurane-
LPS animals (P¼ 0.44, Fig. 5a to e).
Microglia in the cortex (RSC), assessed by Iba-1 positive
cells, was not altered in LPS animals nor by the type
of sedation.
Activation of astrocytes in sepsis
Astrogliosis, assessed by positively GFAP staining in the
hippocampal dentate gyrus region, was increased in
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Haemodynamic stability was verified in lipopolysaccharide and in sham (phosphate-buffered saline) animals under both sedative regimens with either
propofol or sevoflurane (a). Acidosis was comparable in the two lipopolysaccharide groups (b). The systemic inflammatory markers cytokine-induced
neutrophil chemo-attractant protein-1 (c), monocyte chemo-tactic protein-1 (d) and IL-6 (e) were increased at defined time-points in
lipopolysaccharide animals and successfully attenuated in endotoxaemic animals sedated with sevoflurane. P less than 0.05 propofol-
lipopolysaccharide vs. sevoflurane-lipopolysaccharide.
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propofol-LPS and sevoflurane-LPS animals vs. propofol-
PBS (323 64 and 370 105 vs. 150 49 cellsmm2,
both P< 0.001). However, no difference with respect
to the type of sedation in the two sepsis groups was
observed (P¼ 0.57, Fig. 6a to e). In the cortical region,
almost no activated astrocytes in LPS animals were found
(figure not shown).
Impact of sepsis on blood–brain barrier
The blood–brain barrier function was indirectly assessed
by determination of brain water. Brain water content was
similar in control animals and in animals treated with
LPS (propofol-PBS vs. propofol-LPS: 79.71 0.27 vs.
79.53 0.33%, P¼ 0.70 and sevoflurane-PBS vs. sevo-
flurane-LPS: 79.67 0.41 vs. 79.16 0.29%, P¼ 0.05).
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Also, there was no significant difference between the two
LPS groups (P¼ 0.22).
Impact of sepsis on cerebral cell injury
By using TUNEL staining, no apoptotic cells were
observed in the hippocampal and cortical areas of the
animals after 12 h (the ‘Material and methods’ section,
Fig. 1b, data not shown).
Discussion
The current study demonstrates enhanced expression of
cytokines in the blood and brain of animals treated with
LPS. After 12 h of sepsis, neutrophils were recruited into
brain tissue in parallel with activation of macrophages
(microglia) and an increase in astrogliosis, predominantly
located in hippocampal tissue. No structural brain dam-
age such as apoptosis or necrosis was observed. Although
sevoflurane successfully reduced inflammatory mediators
in the blood, endotoxin-induced neuro-inflammation
remained.
Septic encephalopathy is common in severe inflam-
mation and is regarded as a serious complication9–11
with poorly understood pathogenesis and a lack of
treatment options. Intravenous LPS administration
induces systemic inflammation29 and does affect the
central nervous system (CNS).17,30 We considered it a
useful model for investigating neuro-inflammation in
sepsis. Given that sevoflurane has a well known
anti-inflammatory action during sepsis,22–25 we were
interested in exploring the effect of the volatile anaes-
thetic on neuronal inflammation after LPS exposure
in rats.
The three inflammatory mediators CINC-1, MCP-1 and
IL-6 do not only play a crucial role in endotoxaemia, but
are also activated during inflammatory processes in the
brain. CINC-1 (¼CXCL1) is a well known and highly
efficient chemo-attractant for neutrophils.31 Its produc-
tion in astrocytes is induced following neuronal injury,32
and it contributes to neutrophil invasion into the brain33
and to demyelination.34 MCP-1 is a key attractor of
monocytes and macrophages to sites of inflammation.35
It is induced in brain tissue after systemic LPS-chal-
lenge.36 Three facts, namely that MCP-1 (¼CCL2)
receptors are expressed by astrocytes,37 neurons38 and
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microglia,39 and that attenuation of MCP-1 was shown to
be beneficial in sepsis in general,40 and that severity of
neuro-inflammation was reduced in MCP-1-knockout
mice in endotoxin injury,41 all indirectly underline the
importance of MCP-1 as a sustaining factor for neuro-
inflammation. MCP-1 contributes to blood–brain barrier
disruption. It is not only secreted by immune cells, but
also by neurons, astrocytes, microglia and brain endothe-
lial cells.42IL-6 appears to be a predictor for mortality in
septic patients.43 In the brain IL-6 accumulates in ex-
perimental sepsis.44 Its abundance in the brain, appears
to be associated with severe cognitive impairment45 and
neuronal loss.46
In the proposed model, increased systemic levels of the
pro-inflammatory mediators CINC-1, MCP-1 and IL-6
were attenuated in the presence of sevoflurane. This is in
line with previous in-vivo and in-vitro findings.28,47,48
CINC-1 mRNA and protein as well as MCP-1 mRNA
were significantly upregulated in brain tissue in
sepsis.49–51 However, despite the systemic attenuating
effect of sevoflurane, no differences were observed
between propofol and sevoflurane sedation. However,
by limiting the time to sacrifice the animals to 12 h does
not permit full orchestration of the inflammatory re-
sponse to systemically applied LPS in the brain. Media-
tors measured in the blood peak as early as 2 h following
772 Beck-Schimmer et al.
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LPS, whereas the samemediators are discovered at a later
time point in neuronal tissue with a peak between 8 and
12 h.52 Markers of microglia activation are observed 4 to
6 h after LPS challenge, and they remain detectable for
up to 12 h.52 Activated GFAP-positive astrocytes are
detectable as early as 6 h after LPS challenge53 with a
maximal response after 24 to 48 h.52 Taking all these
factors into account we concluded that the 12-h-time-
point allows assessment of inflammatory mediators,
reflecting a late phase of mediator expression. At the
same time, determination of cellular activation of micro-
glia and astrocytes by using Iba-1 and GFAP may be
possible, which represents a rather early time-point for
cellular changes. As a consequence, we cannot exclude
that significant immuno-modulation by sevoflurane may
be evident at a different time-point. A longer experiment
would have been desirable but would require a greater
number of animals, something that may not accord with
the aim of following the 3R principles in animal work.54
Of note is that the IL-6 protein expression in the brain is
different than IL-6 mRNA with a significant difference
between sham and LPS animals, whereas protein levels
do not show this difference. This may be due to the later
protein synthesis following mRNA expression.
In the current study, we did not focus on cytokine
regulation alone, but rather aimed to cover a more com-
plete picture of the neuro-inflammatory response, espe-
cially on a cellular level. Although in our model overall
neutrophil count – assessed by MPO positive cells – was
low, we found a significantly increased number of MPO
positive cells in LPS animals. This correlates with
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elevated mRNA and protein levels of CINC-1 and in-
creased ICAM-1 mRNA expression. An additional group
of inflammatory cells, microglia, are resident in the brain
and represent a group of major active immune cells in the
CNS.55 Persistent activation of microglia may ultimately
result in neuro-degeneration.56 In our study, we found an
increase in Iba-1 immuno-stained cells in the hippocam-
pus, the most vulnerable brain region during sepsis.51
Astrocytes in addition to microglia are important as
structural cells of the brain and are important contributors
to the inflammatory response of the CNS.55 A character-
istic protein of the cells is GFAP, which can be upregu-
lated in response to inflammation.57 Our data show a
significant increase in GFAP positive cells in the dentate
gyrus after LPS challenge. This microglial and astroglial
activation following injury is in line with previous reports
and reviews.18,51,56,58 Other researchers described in-
volvement of hippocampal, microglial and astroglial cells
at later time-points after LPS challenge, after 24 and 72 h,
respectively.59,60 This discrepancy might be due to
different LPS concentrations, routes of administration
(intra-peritoneal, intrathecal) or animal models (mice).
No structural damage of the brain in sepsis was found in
our model. Neither induction of apoptosis, assessed by
TUNEL-positive cellular staining nor alterations in brain
water content, as a measure of brain oedema, could be
demonstrated when comparing sham and LPS animals.
Like all research, our experimental approach has
strengths and limitations. The animal model used is well
established and generates reproducible data with regard
to the inflammatory response.24,28 By using continuous
monitoring and sedation, mechanical ventilation, and a
fluid resuscitation protocol, it was closer to an ICU setting
than many other studies. Nevertheless, we are aware that
a direct translation from animal data to a clinical setting is
not possible for a number of reasons.61 First, a single LPS
challenge is not likely to mimic all aspects of the inter-
active inflammatory response of human sepsis.56,62
Second, tissue evaluation at a single time-point does
not provide details of development over time, neither
does it help with the long-term neurological sequelae of
sepsis.63 Third, rather young male animals were used in
this study. The effect of anaesthetics64 and immune
response may be age65,66 and sex related67 with older
individuals being more prone to cognitive dysfunction.68
Finally, with this first basic analysis of neuro-inflamma-
tion during endotoxaemia, cognitive impairment was not
assessed in our animals. This is a complex task and clearly
not within the expertise of our team.
Conclusion
Our study confirms a systemic anti-inflammatory effect of
sevoflurane compared with propofol in a model of LPS-
induced sepsis in rats. There were no differences in
markers of neuro-inflammation between the sevoflurane
and propofol group within the first 12 h following LPS
injection. Further investigations, including analysis at
multiple time points and long-term assessments of neu-
rologic outcomes that include functional evaluation, are
necessary to confirm these results in vivo, followed by
clinical trials.
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